CVS Health announced on Tuesday that it has reached a proposed settlement with the Federal Trade Commission related to insulin pricing. The company said the agreement involves its pharmacy benefit management arm, Caremark, which it described as having long prioritized efforts to reduce prescription drug costs.
CVS indicated that it expects the settlement process to finish in the coming weeks, but it emphasized that the final terms had not yet been finalized and will be confirmed when the settlement is formally executed.
A person familiar with the settlement said the framework of CVS’ arrangement mirrors the terms the FTC negotiated with Express Scripts, the pharmacy benefit manager owned by Cigna. That earlier deal was completed two weeks after it was proposed, and the source said CVS’ settlement could be implemented even sooner.
The preexisting agreement with Cigna required that company to limit the use of rebate pricing, a practice in which a drugmaker returns a discount to the pharmacy benefit manager after a particular drug is dispensed. Regulators have criticized rebate pricing on the grounds that it can encourage higher list prices and steer beneficiaries toward medicines that generate larger rebates.
Cigna’s settlement also obligated the company to increase transparency and to transition toward a fee-based compensation model for its PBM operations. The agreement included provisions that violations of its terms could prompt additional regulatory action or financial penalties.
J.P. Morgan analyst Lisa Gill said changes to how Caremark prices drugs will likely have only a nominal effect on CVS’ earnings. Gill added that the measures are largely manageable and are not broader than the modifications CVS had already been implementing to address regulatory concerns and to reduce risk within its PBM business. She noted that the adjustments would serve to eliminate regulatory risks for the company.
Should you be buying CI right now? ProPicks AI evaluates CI alongside thousands of other companies every month using more than 100 financial metrics. The tool analyzes fundamentals, momentum, and valuation to generate stock ideas without bias. It highlights past notable winners such as Super Micro Computer (+185%) and AppLovin (+157%). The service offers to show whether CI currently appears in any ProPicks AI strategies or if there are other opportunities in the same sector.
Context and next steps
CVS’ announcement frames the settlement as part of ongoing efforts to address scrutiny of pharmacy benefit managers, which have been the subject of regulatory and legislative attention for their role in shaping how drugs are covered and reimbursed by health plans. While CVS expects the settlement process to conclude soon, the company has not provided or confirmed the final legal terms until the agreement is formally signed.